AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
New long-term and real-world data about risankizumab and upadacitinib may influence treatment choices and expectations about symptom relief, steroid-sparing effects, treatment persistence, and hospitalization risk for people with Crohn's disease or ulcerative colitis.
Adults with Crohn's disease or ulcerative colitis, people on or considering biologic/JAK therapies, clinicians managing IBD, and researchers tracking real-world and long-term treatment outcomes.
What To Know
AbbVie's press release summarizes 18 abstracts it presented at DDW 2026, focusing on long-term and real-world data for risankizumab (SKYRIZI) and upadacitinib (RINVOQ) in Crohn's disease and ulcerative colitis.
The release highlights sustained symptom and endoscopic improvements, reduced steroid use, lower real-world switching rates for risankizumab versus other biologics, and lower hospitalization/ED odds after switching to upadacitinib versus dose escalation.
It also references phase 3 data in perianal fistulizing Crohn's disease showing endoscopic improvements with upadacitinib. This is a company press release summarizing multiple abstracts and real-world analyses rather than a peer-reviewed study report.
It is useful for awareness of new data presented at DDW but does not replace reading the individual abstracts or independent studies for details. If you want details that affect care decisions (like exact outcomes, populations, or safety data), look up the individual DDW abstracts or peer-reviewed publications noted in the release.
This is a company-issued press release summarizing multiple DDW abstracts and real-world analyses. Abstracts and full study details should be consulted for methods, exact results, and safety data. Press releases can emphasize favorable findings; independent review is recommended before changing treatment.
